A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Key claim: Ruxolitinib plus abemaciclib is being tested for safety and efficacy in primary and post-PV/post-ET myelofibrosis.
Abstract
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Why this matters
CDK4/6 inhibition is well established in oncology (breast cancer) but essentially untested in MPNs; pairing abemaciclib with ruxolitinib probes whether blocking cell-cycle progression in JAK/STAT-primed clones can deepen responses beyond spleen/symptom control. As a mechanistically novel add-on, it broadens the ruxolitinib combination portfolio into cell-cycle biology — distinct from BET, XPO1, BCL-2, PI3Kδ, and anemia-directed partners already in trials.